News
Clarametyx Biosciences Strengthens Scientific Advisory Board With Expert Appointments to Advance Pipeline Programs
CLARAMETYX BIOSCIENCES STRENGTHENS SCIENTIFIC ADVISORY BOARD WITH EXPERT…
Clarametyx Biosciences Announces Positive Topline Data from Phase 2a Study Evaluating CMTX-101 in Cystic Fibrosis
CLARAMETYX BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2A STUDY…
Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress
CLARAMETYX BIOSCIENCES STRENGTHENS LEADERSHIP TEAM TO ACCELERATE PIPELINE AND…
Clarametyx Biosciences Announces Completion of Enrollment in Phase 2a Study of CMTX-101 in Cystic Fibrosis
CLARAMETYX BIOSCIENCES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2A STUDY OF…
Clarametyx Biosciences Announces FDA Grant of Fast Track And Qualified Infectious Disease Product Designations For CMTX-101
CLARAMETYX BIOSCIENCES ANNOUNCES FDA GRANT OF FAST TRACK AND QUALIFIED…
Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study Evaluating CMTX-101 for Infections Associated with Cystic Fibrosis
Clarametyx Biosciences Announces Positive Interim Analysis in Phase 2a Study…
CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies for Chronic Respiratory Disease
CincyTech Invests in Clarametyx to Advance Breakthrough Anti-Biofilm Therapies…
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund…
Clarametyx Biosciences Awarded a Multi-Phased Agreement with CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial Infections
Clarametyx Biosciences Awarded a Multi-Phased Agreement with CARB-X to…
Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough Awards
Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the…